Development of enthesopathy in the mouse model of X-linked hypophosphatemia
X连锁低磷血症小鼠模型附着点病变的进展
基本信息
- 批准号:10117441
- 负责人:
- 金额:$ 39.36万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-02-01 至 2026-01-31
- 项目状态:未结题
- 来源:
- 关键词:AblationAddressAffectAgeAgonistAttenuatedBlocking AntibodiesBone DiseasesCYP27B1 geneCartilageCellsChondrocytesClinical ResearchClinical TrialsComplicationDataDevelopmentDihydroxycholecalciferolsDiseaseEnthesopathiesErinaceidaeExhibitsFamilial hypophosphatemic bone diseaseFutureGene ExpressionGenesHistologicHormonalHormonesHumanHypertrophyHypophosphatemiaIhh proteinImpairmentIndividualInheritedInvestigationKnowledgeLeadLentivirusLigandsMechanical StressMediatingMixed Function OxygenasesMolecularMusMutationOsteomalaciaPainPathogenesisPathogenicityPathologicPathway interactionsPatientsPhenotypePlayPreventionProductionProteoglycanRegulationRicketsRoleSerumSignal PathwaySignal TransductionSignaling ProteinSiteStainsTendon structureTimeVitamin DVitamin D3 Receptorachilles tendonautocrinebonebone morphogenic proteincartilage developmentdesigngrowth differentiation factor 5hormone regulationhuman dataimmunoreactivityimprovedmRNA Expressionmineralizationmotor impairmentmouse modelmuscle stressmutant mouse modelnovelnovel therapeuticsparacrinepatellar tendonpreventprospectiveresponserestorationscleraxissmoothened signaling pathwaytendon developmenttherapeutic target
项目摘要
X-linked hypophosphatemia (XLH) is the most common form of inheritable rickets characterized by
mutations in PHEX. These mutations result in elevated serum levels of FGF23, which leads to
hypophosphatemia, rickets, and osteomalacia. FGF23 also inhibits vitamin D 1-a-hydroxylase (Cyp27b1), thus
blocking 1,25 dihydroxyvitamin D (1,25D) production. Pathologic mineralization of the enthesis (tendon-bone
attachment site), referred to as enthesopathy, is a debilitating complication of XLH that causes significant pain
and impaired mobility in affected individuals. Common sites affected include the patellar and Achilles entheses.
The pathogenesis of XLH enthesopathy is poorly understood. We previously demonstrated that Achilles
entheses from mice with XLH (Hyp) have an expansion of hypertrophic appearing cells (HECs) that exhibit an
aberrant chondrogenic phenotype with enhanced BMP/IHH signaling by P14. Treatment of Hyp mice with
1,25D or a FGF23 blocking antibody (FGF23Ab) early in development (P2) similarly prevented enthesopathy
despite the dramatic increase in FGF23 expression in bone, suggesting impaired 1,25D action underlies the
enhanced BMP/IHH signaling observed in Hyp enthesopathy. In both mice and humans with XLH, 1,25D
therapy cannot reverse enthesopathy, supporting the hypothesis that early restoration of 1,25D is needed to
prevent enthesopathy. The increase in serum 1,25D levels wane post-initiation of FGF23Ab in both mice and
humans with XLH, suggesting FGF23Ab may not be effective in preventing enthesopathy in XLH patients.
There is no data on the effects of optimized 1,25D monotherapy or FGF23Ab on enthesopathy in XLH patients.
Therefore, given the similar responses of mice and humans to 1,25D and FGF23Ab, studies on the hormonal
regulation of XLH enthesopathy are essential to guiding future clinical studies on enthesopathy prevention.
Preliminary data show that XLH enthesopathy results from impaired 1,25D action, not actions specific
to FGF23 or consequences of the Hyp mutation. Studies in Aim I will examine mice with global deletions of
Cyp27b1, FGF23, or both with or without the Hyp mutation to address the hypothesis that impaired 1,25D
action leads to enhanced BMP/IHH signaling and enthesopathy. Studies will also elucidate if decreased local
1,25D action leads to enthesopathy. Since our data demonstrates increased BMP signaling is accompanied by
enhanced GDF5 expression in Hyp entheses, studies in Aim II will identify a pathogenic role for GDF5/BMP
signaling in Hyp enthesopathy development. Studies will determine the time course of GDF5 expression in WT
and Hyp entheses. Ablation of GDF5 in Hyp entheses will define the role of GDF5 in the activation of BMP/IHH
signaling in XLH enthesopathy. Inhibition of BMP signaling in Hyp mice will show that IHH signaling is activated
by BMP signaling in entheses and enhanced BMP/IHH signaling directly leads to enthesopathy. Taken
together, these studies will identify novel hormonal and molecular regulators of XLH enthesopathy and normal
enthesis development. They will also identify targets for the design of new therapies to prevent enthesopathy.
X连锁低磷血症是最常见的遗传性软骨病,其特征是
PHEX基因突变。这些突变导致血清FGF23水平升高,从而导致
低磷血症、软骨病和软骨病。FGF23还抑制维生素D 1-a-羟基酶(Cyp27b1),从而
阻止1,25二羟基维生素D(1,25D)的生产。末端(腱-骨)的病理性矿化
附着点),称为末端病,是XLH的一种使人衰弱的并发症,会引起极大的疼痛
以及受影响个人的行动能力受损。受影响的常见部位包括膝盖骨和跟腱。
XLH型终末病的发病机制尚不清楚。我们之前证明了阿喀琉斯
XLH型(Hyp)小鼠肾小管有肥大细胞(HECs)的扩张,表现为
P14增强的BMP/IHH信号异常的软骨形成表型。复方丹参对Hyp小鼠的治疗作用
1,25D或FGF23封闭抗体(FGF23Ab)在发育早期(P2)类似地预防终末期疾病
尽管FGF23在骨骼中的表达急剧增加,但这表明1,25D作用受损是
在Hyp Enthesis中观察到BMP/IHH信号增强。在患有XLH的小鼠和人类中,1,25D
治疗不能逆转终端病,支持需要早期恢复1,25D的假说
预防末梢病。FGF23抗体诱导小鼠和小鼠血清1,25D水平的升高
提示FGF23Ab可能不能有效预防XLH患者的终末病。
目前还没有关于优化的1,25D单一治疗或FGF23单抗对XLH患者终端病的影响的数据。
因此,考虑到小鼠和人类对1,25D和FGF23抗体的相似反应,对激素的研究
XLH型终末病的调控对于指导今后预防终末病的临床研究具有重要意义。
初步数据显示,XLH型终末症是由1,25D活动受损引起的,而不是特定的行为
FGF23或Hyp突变的后果。在AIM I上的研究将检查具有全局缺失的
Cyp27b1、FGF23或两者都带有或不带有Hyp突变,以解决损害1,25D的假设
ACTION导致BMP/IHH信号增强和终末性病变。研究还将阐明,如果当地人口减少
1,25D作用导致终末病。由于我们的数据显示BMP信号的增加伴随着
增强GDF5在Hyp包膜中的表达,AIM II的研究将确定GDF5/BMP的致病作用
高血压终末病发生发展中的信号转导。研究将确定WT中GDF5表达的时间进程
和Hyp enals。消融包膜中的GDF5将确定GDF5在BMP/IHH激活中的作用
XLH型终末病中的信号转导。抑制Hyp小鼠的BMP信号将表明IHH信号被激活
BMP信号通过末端传递,BMP/IHH信号的增强直接导致末端病变。已被占用
总之,这些研究将确定XLH型终末症和正常的新的激素和分子调节剂。
雌蕊发育。他们还将确定新疗法的设计目标,以预防终末期疾病。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Eva S. Liu其他文献
Eva S. Liu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Eva S. Liu', 18)}}的其他基金
Development of enthesopathy in the mouse model of X-linked hypophosphatemia
X连锁低磷血症小鼠模型附着点病变的进展
- 批准号:
10329988 - 财政年份:2021
- 资助金额:
$ 39.36万 - 项目类别:
Development of enthesopathy in the mouse model of X-linked hypophosphatemia
X连锁低磷血症小鼠模型附着点病变的进展
- 批准号:
10548844 - 财政年份:2021
- 资助金额:
$ 39.36万 - 项目类别:
Molecular and cellular determinants of enthesopathy in X-linked hypophosphatemia
X连锁低磷血症中附着点病变的分子和细胞决定因素
- 批准号:
8867825 - 财政年份:2015
- 资助金额:
$ 39.36万 - 项目类别:
Molecular and cellular determinants of enthesopathy in X-linked hypophosphatemia
X连锁低磷血症中附着点病变的分子和细胞决定因素
- 批准号:
9314995 - 财政年份:2015
- 资助金额:
$ 39.36万 - 项目类别:
Comparative effectiveness of therapeutic modalities in X-linked hypophosphatemia
X连锁低磷血症治疗方式的疗效比较
- 批准号:
8592727 - 财政年份:2013
- 资助金额:
$ 39.36万 - 项目类别:
Comparative effectiveness of therapeutic modalities in X-linked hypophosphatemia
X连锁低磷血症治疗方式的疗效比较
- 批准号:
8788783 - 财政年份:2013
- 资助金额:
$ 39.36万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 39.36万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 39.36万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 39.36万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 39.36万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 39.36万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 39.36万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 39.36万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 39.36万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 39.36万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 39.36万 - 项目类别:
Research Grant